Stem Cell Therapy Risks and Side Effects: A Patient Guide

Sunday evening at the kitchen table. The informed consent PDF on the laptop screen, ten pages, with the patient’s electronic signature line at the bottom. The procedure scheduled for nine days out. The consultation had not pretended the procedure was zero-risk. The patient’s spouse, across the table, had not said the decision was easy. The second opinion had not reversed the candidacy assessment. The patient was at the final review point. The procedure was scheduled for nine days out. The Sunday evening question was whether the patient understood the risks well enough to sign the document, and whether the document represented the same risk profile the published research describes.

This guide walks through the risks and side effects associated with stem cell therapy, with separate attention to the predictable mild effects, the less common but documented serious adverse events, the risks that are specifically tied to procedure-site issues, and the risks that are substantially higher outside FDA-regulated treatment settings. The patient at the informed-consent moment should know what each category looks like before signing.

Which Common Mild Side Effects Most Patients Experience

The published systematic review at NIH PubMed Central of complications from stem cell-based injections for knee osteoarthritis, including nearly 2000 patients, documents the typical mild side effect profile:

Soreness, swelling, and warmth at the injection site lasting up to 4 weeks
Increased pain at the target joint during the early inflammatory pro-repair window, sometimes more pronounced than the underlying chronic pain
Transient stiffness in the joint during the first one to two weeks
Mild bruising at the injection or harvest site
Brief vasovagal response (lightheadedness) during the procedure in some patients
Minor procedural discomfort during the injection or harvest itself

The transient adverse event rate across the systematic review studies was 12.3 percent, with most events resolving within a defined window without medical intervention. These mild effects are generally part of the expected procedure response rather than complications, and patients should know to expect them rather than treat them as warning signs.

Where Less Common but Documented Adverse Events Have Occurred

Less common but documented adverse events from stem cell-based injections include:

Infection at the injection site, ranging from local skin infection to deeper joint infection, with rates that vary across studies but generally remain low at FDA-regulated settings
Significant joint swelling or effusion requiring drainage in rare cases
Allergic reactions to processing agents or, in allogeneic settings, to donor cell components
Persistent procedure-site discomfort beyond the typical 4-week window
Bleeding complications, particularly in patients on anticoagulants without appropriate adjustment
Rare cases of cell migration or unintended distribution outside the target tissue

The NIH systematic review found no reports of serious complications such as sepsis, infection requiring hospitalization, neoplasm, or death across the nearly 2000 patients reviewed in studies of autologous mesenchymal stem cell injections at qualified treatment settings. The accurate patient-facing summary is that serious adverse events are rare in autologous regenerative procedures performed at qualified clinics.

What Procedure-Site Risks Apply at Injection and Harvest Locations

Procedure-site risks differ between the harvest location and the injection location, with each carrying its own profile:

Bone marrow harvest site (iliac crest):

Soreness for several days, sometimes longer in patients with thinner soft tissue cover
Bruising at the harvest site
Rare hematoma formation requiring medical attention
Very rare bone-related complications

Adipose harvest site (abdomen or flank):

Soreness and bruising at the lipoaspiration site
Mild cosmetic change in some patients (small contour irregularity)
Rare seroma or hematoma formation
Very rare deep vein thrombosis with extended immobility

Injection site (target joint or tendon):

Local soreness, swelling, and warmth as discussed above
Risk of injection-related infection (low but not zero)
Rare cases of needle-related neurovascular injury with landmark-only injections (lower with image guidance)

The image-guidance disciplines covered in the ultrasound-guided injection guide reduce several of the injection-site risks. Procedures performed under real-time ultrasound have documented advantages in needle accuracy and avoidance of at-risk structures along the needle path.

Why Risks Are More Likely Outside FDA-Regulated Settings

The risk profile differs substantially between procedures performed under appropriate FDA framework compliance and procedures performed at clinics operating outside that framework. The FDA Patient and Consumer Warning About Potential Serious Risks, the agency’s current consumer-facing guidance, documents the harms specifically associated with unapproved products:

Bacterial infections from cross-contamination during processing, including septicemia (life-threatening blood infection)
Tumor formation, lesions, or other abnormal growths from cell migration or differentiation outside the target tissue
Blindness from intraocular fat-derived treatments at one Florida clinic, with documented cases involving severe vision loss
Paraplegia, pulmonary embolism, cardiac arrest, organ damage, and death documented in adverse event reports
Severe inflammation of the central nervous system in some patients with unapproved neurological stem cell treatments
Exposure to infectious diseases (hepatitis, HIV, others) when products are not appropriately tested

The Pew Charitable Trusts review of harms linked to unapproved stem cell interventions, citing FDA case reports, documented at least 35 cases of serious complications, 10 of which resulted in death and 18 of which were associated with neurological-condition treatments. The risk distribution is not symmetric. Procedures at FDA-regulated clinics with appropriate documentation, qualified personnel, and proper processing have substantially lower documented serious adverse event rates than procedures at clinics operating outside the regulatory framework.

The patient considering treatment should know that part of the procedure’s safety depends on choosing a clinic operating within the framework rather than outside it. The Federal Trade Commission has brought enforcement actions against clinics making deceptive marketing claims while operating in regulatory non-compliance, with the underlying safety record providing context for why the regulatory position matters.

How Patient Factors Affect Adverse Event Likelihood

Several patient-specific factors affect the likelihood of adverse events from stem cell therapy:

Active infection at the time of procedure substantially increases risk
Anticoagulant therapy without appropriate adjustment increases bleeding complications
Severe immune dysfunction increases susceptibility to procedure-related infection
Multiple comorbidities (advanced cardiac, kidney, or liver disease) affect overall procedural risk
Smoking and tobacco use affect tissue healing and infection susceptibility
Diabetes with poor glycemic control affects healing and infection risk
Allergies to specific processing agents or cell preservatives affect compatibility with specific protocols

The candidacy evaluation discussed in the candidacy guide is, in part, a risk-management exercise. Patients with documented risk factors should expect the consultation to address them either through pre-procedure optimization or through reconsideration of whether the procedure is the right intervention.

Informed Consent: What a Quality Clinic Discloses Before Treatment

A quality informed consent process for stem cell therapy includes several elements the patient should encounter:

Clear explanation of the specific product, source, and processing protocol
Disclosure of the FDA regulatory pathway (Section 361, Section 351 with IND, or other) under which the product is offered
Discussion of the published research base for the specific application, including effect sizes and limitations
Detailed disclosure of common mild side effects and the typical timeline
Disclosure of less common but documented serious adverse events
Discussion of procedure-site risks for both harvest and injection locations
Discussion of patient-specific factors that affect the patient’s risk profile
Disclosure of the calibrated response expectations and the comparison to alternative treatments
Time for the patient to review documentation, ask questions, and consult with family or other clinicians before committing
Documentation of the consent discussion in the medical record

A consultation that runs through these elements with calibrated language and complete documentation is operating at the informed-consent standard the procedure expects. A consultation that produces only a signature page without the underlying disclosure conversation is operating below that standard, and the patient who notices the gap has identified one of the markers the FDA and FTC have repeatedly cited in enforcement actions.

The Sunday evening informed consent PDF that started this guide ends with the patient’s electronic signature pending. The procedure remains scheduled for nine days out. The risk profile, the candidacy factors, and the regulatory framework are all clearer now than they were when the document first opened. The decision to sign or not, when it happens, often tends to come from a careful read of the disclosed risks alongside what the consultation has documented about the specific procedure and clinic. The choice is genuinely the patient’s. The information needed to make the choice is what the informed-consent process is designed to deliver.

Important note on risk decisions: No clinic selection framework guarantees outcomes, and regional availability and individual candidacy factors shape what each patient encounters. The realistic question is what specific criteria the patient applies to clinic evaluation and what professional input, including primary care, specialist consultation, and second opinion, supports a sound decision.

Sources: